Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX: QL1706 + Bevacizumab + Chemotherapy in PD-L1 ≥50% NSCLC with Actionable Genomic Alterations
NCT07416058Phase 2Recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started Apr 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07416058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416058.